In our study, STAT3 inhibition was effective in the PC9-BM model but not in the A549 model, suggesting that LCN2 expression may serve as a predictive biomarker for STAT3-targeted therapy in lung cancer BM. The gene discussed is STAT3; the disease is lung carcinoma.